Immune checkpoint inhibitors (ICIs) have become a treatment option for many patients with advanced melanoma. Still, the chances of long-term success of ICIs for advanced melanoma remain only about 50% ...
HealthDay News — For patients with resected stage IIIB-C or stage IV melanoma, recurrence-free survival is longer with nivolumab than ipilimumab, according to a study published online Oct. 18 in the ...
Please provide your email address to receive an email when new articles are posted on . The addition of nivolumab to ipilimumab prolonged survival for patients with advanced melanoma. Nivolumab ...
Erratum: Randomized Comparison of Intensified Six-Drug Versus Standard Three-Drug Chemotherapy for High-Risk Nonmetastatic Rhabdomyosarcoma and Other Chemotherapy-Sensitive Childhood Soft Tissue ...
Median survival increased by about 3.7 months compared to those given a gp100 cancer vaccine. Melanoma patients treated using Bristol-Myers Squibb’s (BMS) human CTLA-4 mAb candidate, ipilimumab, ...
More than half of melanoma patients whose cancer initially responds to immunotherapy will eventually see their disease return ...
LOS ANGELES, May 14 (Reuters) - More than a third of advanced melanoma patients treated with ipilimumab, an antibody being developed by Bristol-Myers Squibb Co and Medarex Inc , continued to survive ...
The idea that patients could get better responses with shorter courses of therapy runs counter to the current standard of care in melanoma. Giving patients with resectable stage III melanoma a ...
Impact of 18F-Labeled Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Versus Conventional Staging in Patients With Locally Advanced Breast Cancer In total, 533 patients received at ...
Detailed price information for Replimune Group Inc (REPL-Q) from The Globe and Mail including charting and trades.
The median duration of recurrence-free survival was 61.1 and 24.2 months with nivolumab and ipilimumab, respectively, at a minimum follow-up of 107 months. HealthDay News — For patients with resected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback